Clinical Characteristics and Pregnancy-Related Outcomes of Pregnant Women Hospitalized with COVID-19 During the Delta Wave: A Single-Center Observational Study
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background: Coronavirus disease 2019 (COVID-19) during pregnancy is associated with increased disease severity and an increased risk of perinatal complications. However, few studies of pregnant women with COVID-19 have been conducted in Korea. The purpose of this study was to describe the clinical course and pregnancy outcomes of pregnant women admitted to our hospital with COVID-19 according to the severity. Materials and methods: This retrospective cohort study included women aged 18 years of age or older who were hospitalized in the Gachon University Gil Medical Center with COVID-19 during pregnancy between July 1, 2021 and January 31, 2022. COVID-19 severity was classified according to the "Criteria for severity classification by symptoms of COVID-19" presented by the Korea Disease Control and Prevention Agency. Severe cases were defined as those who required oxygen treatment administered via a high-flow nasal cannula or invasive mechanical ventilation or should be applied extracorporeal membrane oxygenation (ECMO) or continuous renal replacement therapy. Results: A total of 103 pregnant women were hospitalized with COVID-19 during the study period. Their mean age was 33 (± 4.14) years, and 4 (3.9%) had been vaccinated against COVID-19. At the time of diagnosis of COVID-19, 3 (2.9%), 33 (32.0%), and 67 (65.1%) patients were in the first, second, and third trimester, respectively. The most common symptoms were cough (99 patients, 96.1%) and fever (85 patients, 82.5%). There was 1 (1.0%) asymptomatic patient. Forty patients (38.8%) required supplemental oxygen and 19 patients (18.4%) had severe disease. Of the 19 severe cases, 7 were in the 2nd trimester and 12 were in the 3rd trimester. Forty-one (39.8%) patients delivered, including two twin deliveries. Of the 41 cases of delivery, 14 were premature, 4 out of 21 (19.0%) in mild, 4 out of 12 (25.0%) in moderate, and 6 out of 8 (75.0%) in severe. Severe disease was associated with an increased rate of preterm birth (P = 0.012). Four of the 43 neonates (9.1%) received oxygen treatment. Conclusion: Pregnant women with COVID-19 had a high rate of severe disease and a high preterm delivery rate, especially among those with severe disease.
Abstract
Background: Coronavirus disease 2019 (COVID-19) during pregnancy is associated with increased disease severity and an increased risk of perinatal complications. However, few studies of pregnant women with COVID-19 have been conducted in Korea. The purpose of this study was to describe the clinical course and pregnancy outcomes of pregnant women admitted to our hospital with COVID-19 according to the severity. Materials and methods: This retrospective cohort study included women aged 18 years of age or older who were hospitalized in the Gachon University Gil Medical Center with COVID-19 during pregnancy between July 1, 2021 and January 31, 2022. COVID-19 severity was classified according to the "Criteria for severity classification by symptoms of COVID-19" presented by the Korea Disease Control and Prevention Agency. Severe cases were defined as those who required oxygen treatment administered via a high-flow nasal cannula or invasive mechanical ventilation or should be applied extracorporeal membrane oxygenation (ECMO) or continuous renal replacement therapy. Results: A total of 103 pregnant women were hospitalized with COVID-19 during the study period. Their mean age was 33 (± 4.14) years, and 4 (3.9%) had been vaccinated against COVID-19. At the time of diagnosis of COVID-19, 3 (2.9%), 33 (32.0%), and 67 (65.1%) patients were in the first, second, and third trimester, respectively. The most common symptoms were cough (99 patients, 96.1%) and fever (85 patients, 82.5%). There was 1 (1.0%) asymptomatic patient. Forty patients (38.8%) required supplemental oxygen and 19 patients (18.4%) had severe disease. Of the 19 severe cases, 7 were in the 2nd trimester and 12 were in the 3rd trimester. Forty-one (39.8%) patients delivered, including two twin deliveries. Of the 41 cases of delivery, 14 were premature, 4 out of 21 (19.0%) in mild, 4 out of 12 (25.0%) in moderate, and 6 out of 8 (75.0%) in severe. Severe disease was associated with an increased rate of preterm birth (P = 0.012). Four of the 43 neonates (9.1%) received oxygen treatment. Conclusion: Pregnant women with COVID-19 had a high rate of severe disease and a high preterm delivery rate, especially among those with severe disease.
참고문헌 (31)
- "WHO Coronavirus (COVID-19) dashboard"[URL]
- Harrison SL, "Comorbidities associated with mortality in 31, 461 adults with COVID-19 in the United States : A federated electronic medical record analysis", PLoS Med, 17, pp.e1003321~ (2020)
- "Science Brief: Evidence used to update the list of underlying medical conditions associated with higher risk for severe COVID-19"[URL]
- Jamieson DJ, "An update on COVID-19 and pregnancy", Am J Obstet Gynecol, 226, pp.177~186 (2022)
- Allotey J, "Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis", BMJ, 370, pp.m3320~ (2020)
- Chmielewska B, "Effects of the COVID-19 pandemic on maternal and perinatal outcomes : a systematic review and meta-analysis", Lancet Glob Health, 9, pp.e759~e772 (2021)
- Kim SH, "Impact of COVID-19 on pregnant women in South Korea : Focusing on prevalence, severity, and clinical outcomes", J Infect Public Health, 15, pp.270~276 (2022)
- Chung Youseung, "Maternal Outcomes and Clinical Characteristics of COVID-19 in Korean Pregnant Women during the Early Period of the Pandemic", Journal of Korean Medical Science, 36(41), pp.1~7 (2021), 대한의학회[DOI]
- "Central Disaster Management Headquarters, 13th edition of SARS-CoV-2 response guidelines (for local governments), Criteria for severity classification by symptoms of COVID-19"[URL]
- Jafari M, "Clinical characteristics and outcomes of pregnant women with COVID-19 and comparison with control patients : A systematic review and meta-analysis", Rev Med Virol, 31, pp.1~16 (2021)
- Wei SQ, "The impact of COVID-19 on pregnancy outcomes : a systematic review and meta-analysis", CMAJ, 193, pp.E540~E548 (2021)
- "Republic of Korea. COVID-19 outbreak status"[URL]
- Adhikari EH, "Increasing severity of COVID-19 in pregnancy with Delta(B. 1. 617. 2)variant surge", Am J Obstet Gynecol, 226, pp.149~151 (2022)
- Yang S, "COVID-19 Special Report. COVID-19 outbreak report from January 20, 2020 to January 19, 2022 in the Republic of Korea", PHWR, 15, pp.796~805 (2022)
- "2019 birth statistics"[URL]
- "2020 birth statistics"[URL]
- "ACOG Committee Opinion No. 765: Avoidance of nonmedically indicated early-term deliveries and associated neonatal morbidities", Obstet Gynecol, 133, pp.e156~63 (2019)
- Metz TD, "Association of SARS-CoV-2 infection with serious maternal morbidity and mortality from obstetric complications", JAMA, 327, pp.748~759 (2022)
- Prochaska E, "COVID-19 in pregnancy : Placental and neonatal involvement", Am J Reprod Immunol, 84, pp.e13306~ (2020)
- "COVID-19 care recommendations (ver. 2.1)"[URL]
- Choi Seong Jin, "Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study", Infection and Chemotherapy, 54(1), pp.91~101 (2022), 대한감염학회[DOI]
- Burwick RM, "Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019", Clin Infect Dis, 73, pp.e3996~e4004 (2021)
- Eid J, "Early administration of remdesivir and intensive care unit admission in hospitalized pregnant individuals with coronavirus disease 2019(COVID-19)", Obstet Gynecol, 139, pp.619~621 (2022)
- Sammaritano LR, "2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases", Arthritis Rheumatol, 72, pp.529~556 (2020)
- Pasley MV, "Safety and efficacy of lopinavir", ritonavir during pregnancy : a systematic review, 2013, pp.15, 38~48
- Fowler MG, "Benefits and risks of antiretroviral therapy for perinatal HIV prevention", N Engl J Med, 375, pp.1726~1737 (2016)
- "Recommendation by the vaccination committee on COVID-19 vaccinations and booster vaccinations for pregnant women, children and adolescents"[URL]
- "COVID-19 press release, Pre-registration of vaccinations available for pregnant women from October 8 (Fri), and mRNA vaccination available at consigned medical institutions nationwide from October 18 (Mon)"[URL]
- "Weekly data: COVID-19 vaccination among pregnant people aged 18-49 years before and during pregnancy overall, by race/ethnicity, and week ending 4/23/2022"[URL]
- Theiler RN, "Pregnancy and birth outcomes after SARSCoV-2 vaccination in pregnancy", Am J Obstet Gynecol MFM, 3, pp.100467~ (2021)
- Goldshtein I, "Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women", JAMA, 326, pp.728~735 (2021)